Topics
Business & Finance
-
Tuesday - July 14, 2009
New Drug Application for Rivaroxaban in the U.S.:
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA
-
Thursday - July 9, 2009
Expansion of diabetes portfolio in growth market China:
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
-
Wednesday - July 8, 2009
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.
FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding
-
Wednesday - July 1, 2009
Bayer files patent infringement lawsuit against Teva
-
Monday - June 29, 2009
Bayer CropScience and Monsanto sign cross licensing agreement on herbicide tolerance traits in rapeseed/canola
-
Tuesday - June 2, 2009
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement
-
Thursday - May 28, 2009
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
U.S. FDA Issues Complete Response Letter for Rivaroxaban
No new clinical or non-clinical studies to be conducted as a pre-requisite for approval
-
Tuesday - May 26, 2009
Sustainable Development Report 2008 published:
Bayer: Successful and sustainable business
Investment in the future: R&D budget of EUR 2.9 billion / Contributing solutions to global challenges: Global access to medicines, feeding the world population, water protection, climate change / Intensive social commitment: EUR 50 million for education, social needs, environmental protection, culture and sports
-
Wednesday - May 20, 2009
FTSE4Good indices and the European Risk Management Award:
Bayer honored for sustainability and climate protection
Dr. Plischke of Bayer’s Management Board: “Sustainability has great relevance for us”
-
Wednesday - May 20, 2009
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
-
Thursday - May 14, 2009
Qlaira® – innovative estradiol-based oral contraceptive available in Europe from May onwards
A new oral contraceptive delivering the same estrogen as produced by the female body
-
Tuesday - May 12, 2009
Werner Wenning at the Bayer AG Annual Stockholders’ Meeting
“Corporate strategy proves effective in a difficult environment”
Earnings targets met in 2008 / Proposed 3.7 percent increase in dividend, to EUR 1.40 per share / CropScience and Pharmaceuticals remain on a path of growth in the current year / Group targets increasingly demanding following the slump in business at MaterialScience
-
Tuesday - May 12, 2009
The Fascination of Bayer visualized in spectacular images
Bayer presents new corporate image film
Premiere at the Annual Stockholders’ Meeting in Düsseldorf
-
Tuesday - May 5, 2009
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
-
Tuesday - May 5, 2009
Berlin Energy Days: Award for Project of Bayer Climate Program
Climate-Neutral Bayer Child Care Center Receives Accolade from German Economics Ministry
-
Thursday - April 30, 2009
Bayer and Regeneron extend development program for VEGF Trap-Eye
Two phase III studies in Central Retinal Vein Occlusion (CRVO) to begin in the second half of this year
-
Wednesday - April 29, 2009
Bayer interim report for the first quarter of 2009
CropScience and Pharmaceuticals continue on a path of growth – Slump in business at MaterialScience leaves a distinct mark
Group sales: EUR 7,895 million (minus 7.5 percent) / EBITDA before special items: EUR 1,695 million (minus 22.4 percent) / EBIT before special items: EUR 1,017 million (minus 32.1 percent) / Net cash flow: EUR 693 million (plus 31.3 percent)
-
Tuesday - April 28, 2009
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
-
Monday - April 27, 2009
Phase III Trial of Nexavar® in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Study stopped based on interim analysis
-
Friday - April 3, 2009
Strengthening the international production network:
Bayer CropScience invests EUR 30 million in expansion of crop protection production at the Dormagen Chemical Park
Active substance Prothioconazole controls fungi that can harm human health
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection